≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback
info icon

This is a non-core endpoint: only basic statistics are computed.

Chondrosarcoma

EFO Endpoint Browser

C3_CHONDROSARCOMA

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Cause of death: ICD-10 — C40.2|C4104|C4106|C4114|C4122|C4132|C4142|C4182|C4192
  • Cancer registry: Topography ICD-O-3 — ANY
  • Cancer registry: Morphology ICD-O-3 — 9220|9230|9231
  • Cancer registry: Behaviour codes — 3

2 out of 7 registries used, show all original rules.

113

4. Check minimum number of events

None

113

5. Include endpoints

None

113

6. Filter based on genotype QC (FinnGen only)

111

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze
DF8

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

-FinnGen-

Key figures

All Female Male
Number of individuals 111 50 61
Unadjusted period prevalence (%) 0.02 0.02 0.03
Median age at first event (years) 56.23 54.63 57.55

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
113
Matched controls
1130
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D48.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bone and articular cartilage
130.2
35.1
36
*
C40.22
ICD-10 Finland
Chondrosarcoma of the long bones of the lower extremity
+∞
30.6
28
*
9220/3-C40.2
ICD-O-3
Chondrosarcoma, NOS, of long bones of lower limb and associated joints
+∞
28.3
26
*
130
Kela drug reimbursment
Malignant tumour
+∞
22.7
21
*
WX408
NOMESCO Finland
General anesthesy, balanced
6.4
21.6
56
151
C41.32
ICD-10 Finland
Chondrosarcoma of the ribs, sternum and clavicle
+∞
18.2
17
*
C40.20
ICD-10 Finland
Malignant tumor of the long bones of the lower extremity without histology
+∞
18.2
17
*
9220/3-C41.3
ICD-O-3
Chondrosarcoma, NOS, of rib, sternum, clavicle and associated joints
+∞
17.1
16
*
C40.02
ICD-10 Finland
Chondrosarcoma of the scapula and long bones of the upper extremity
+∞
14.9
14
*
GAE06
NOMESCO Finland
Excision of lesion of chest wall
+∞
13.8
13
*
H02AB02
ATC
dexamethasone; systemic
57.1
13.2
15
*
C41.82
ICD-10 Finland
Overall chondrosarcoma in bone and articular cartilage
+∞
12.7
12
*
XX3DW
NOMESCO Finland
Time consuming IT work
13.4
12.7
22
20
D16.2
ICD-10 Finland
Benign neoplasm: Long bones of lower limb
72.7
11.9
13
*
9220/3-C41.4
ICD-O-3
Chondrosarcoma, NOS, of pelvic bones, sacrum, coccyx and associated joints
+∞
11.7
11
*
NFR30
NOMESCO Finland
Extended excision of soft tissue tumour of hip or thigh
+∞
11.7
11
*
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
9.8
11.0
22
27
C41.42
ICD-10 Finland
Chondrosarcoma of the pelvic bones, sacrum and coccyx
+∞
10.6
10
*
9220/3-C40.0
ICD-O-3
Chondrosarcoma, NOS, of long bones of upper limb, scapula and associated joints
+∞
10.6
10
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
11.8
10.5
19
19
WX402
NOMESCO Finland
General anaesthesia
4.1
10.5
38
125
ZXE30
NOMESCO Finland
More than five and less than seven hours
19.0
10.2
15
9
B01AB05
ATC
enoxaparin; parenteral
3.6
9.9
51
212
EN1BD
NOMESCO Finland
Very extensive CT examination of mouth and soft tissues of neck
60.3
9.8
11
*
B01AB10
ATC
tinzaparin; parenteral
5.7
9.7
20
41
L03AA13
ATC
pegfilgrastim; parenteral
108.8
9.6
10
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
9.5
9
*
C32.3
ICD-10 Finland
Malignant neoplasm: Laryngeal cartilage
+∞
9.5
9
*
NK6BN
NOMESCO Finland
Bone dynamic isotope examination
+∞
9.5
9
*
WX302
NOMESCO Finland
Thoracal epidural anesthesy
15.5
9.5
15
11
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
26.6
9.1
12
5
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.4
9.0
71
378
R4110
NOMESCO Finland
Physiotherapy
3.3
8.6
47
199
WF002
NOMESCO Finland
Radical radiotherapy
97.0
8.5
9
*
JN4BD
NOMESCO Finland
Extensive body CT
7.9
8.5
19
28
ZXE20
NOMESCO Finland
More than three and less than five hours
4.1
8.4
27
80
9220/3-C41.0
ICD-O-3
Chondrosarcoma, NOS, of bones of skull and face and associated joints
+∞
8.4
8
*
NK6CT
NOMESCO Finland
Bone biopsy with CT guidance
+∞
8.4
8
*
GAE23
NOMESCO Finland
Resection of chest wall and prosthetic repair
+∞
8.4
8
*
C41.3
ICD-10 Finland
Malignant neoplasm: Ribs, sternum and clavicle
+∞
8.4
8
*
C41.06
ICD-10 Finland
Chondrosarcoma of the skull or facial bones except maxilla
+∞
8.4
8
*
ZXE10
NOMESCO Finland
More than one and less than three hours
3.1
8.1
51
234
JN4AD
NOMESCO Finland
Body CT examination
7.2
7.6
18
29
A03FA01
ATC
metoclopramide; systemic, rectal
3.9
7.5
26
81
D38.0
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Larynx
85.5
7.5
8
*
A04AA02
ATC
granisetron; systemic, transdermal
85.5
7.5
8
*
ZXB10
NOMESCO Finland
Medial
85.5
7.5
8
*
QAE10
NOMESCO Finland
Excision of other lesion extending through all layers of skin in head or neck
17.2
7.4
11
7
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
7.4
7
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
7.4
7
*
115
Kela drug reimbursment
Breast cancer
+∞
7.4
7
*
DQB20
NOMESCO Finland
Partial excision of larynx
+∞
7.4
7
*
C40.2
ICD-10 Finland
Malignant neoplasm: Long bones of lower limb
+∞
7.4
7
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
7.4
7
*
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
7.4
7
*
NER30
NOMESCO Finland
Extended excision of soft tissue tumour of pelvis
+∞
7.4
7
*
9220/3-C32.3
ICD-O-3
Chondrosarcoma, NOS, of laryngeal cartilage
+∞
7.4
7
*
C41.22
ICD-10 Finland
Chondrosarcoma of the spine
+∞
7.4
7
*
PJA12
NOMESCO Finland
Sentinel node biopsy
+∞
7.4
7
*
TPH07
NOMESCO Finland
Cathetrisation of artery
4.0
7.3
24
72
WX404
NOMESCO Finland
Intravenous generell anesthesy
3.5
7.3
31
111
GBB00
NOMESCO Finland
Tracheostomy
21.7
7.3
10
5
ZXE40
NOMESCO Finland
More than seven and less than nine hours
42.7
6.8
8
*
ZXD10
NOMESCO Finland
Scheduled procedure
2.8
6.7
54
278
C61
ICD-10 Finland
Malignant neoplasm of prostate
73.8
6.5
7
*
NFB60
NOMESCO Finland
Demanding prosthetic replacement of hip
73.8
6.5
7
*
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
73.8
6.5
7
*
NGR20
NOMESCO Finland
Intralesional or marginal excision of tumor of knee or lower leg
73.8
6.5
7
*
QA1S1
NOMESCO Finland
Photography of skin or subcutaneous tissue in head
73.8
6.5
7
*
NF3AA
NOMESCO Finland
Femur X-ray examination
8.5
6.3
13
17
17071
ICD-8 Finland
Malignant neoplasm of bone, Lower limb, long bones
+∞
6.3
6
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
6.3
6
*
C40.00
ICD-10 Finland
Malignant tumor of the scapula and the long bones of the upper extremity without histology
+∞
6.3
6
*
8500/3-C50.9
ICD-O-3
Infiltrating duct carcinoma, NOS, of breast, NOS
+∞
6.3
6
*
DQD50
NOMESCO Finland
Endoscopic insertion of stent in larynx
+∞
6.3
6
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
6.3
6
*
NBR20
NOMESCO Finland
Intralesional or marginal excision of soft tissue tumour of shoulder or upper arm
+∞
6.3
6
*
WZC30
NOMESCO Finland
Teaching
3.4
6.2
25
86
NG4AA
NOMESCO Finland
Lower leg X-ray examination
10.9
6.2
11
11

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Orthopedic Surgery
20 [38004465]
5.4e-01
1.4e+00
3.0e+00
1.0e+50
4.0e+00
3.3e+00
2.0e+00
cases:18.37%
controls:11.63%
cases:14.29%
controls:3.78%
cases:15.31%
controls:0.92%
cases:12.24%
controls:0.00%
cases:27.84%
controls:0.71%
cases:48.96%
controls:3.40%
cases:54.22%
controls:13.31%
18
114
80
866
14
37
84
943
15
9
83
971
12
0
86
980
27
7
70
973
47
33
49
937
45
117
38
762
Outpatient Visit
OP [9202]
3.3e-01
5.2e-01
2.3e+00
3.4e+00
2.3e+00
2.2e+00
1.9e+00
cases:68.37%
controls:60.92%
cases:53.06%
controls:40.10%
cases:45.92%
controls:7.96%
cases:16.33%
controls:0.61%
cases:49.48%
controls:9.18%
cases:86.46%
controls:42.37%
cases:93.98%
controls:70.42%
67
597
31
383
52
393
46
587
45
78
53
902
16
6
82
974
48
90
49
890
83
411
13
559
78
619
5
260
Outpatient Hospital
22 [8756]
2.6e-01
8.3e-01
3.7e+00
1.0e+50
4.1e+00
2.6e+00
1.1e+00
cases:25.51%
controls:20.82%
cases:11.22%
controls:5.20%
cases:22.45%
controls:0.71%
cases:10.20%
controls:0.00%
cases:26.80%
controls:0.61%
cases:44.79%
controls:5.88%
cases:32.53%
controls:13.54%
25
204
73
776
11
51
87
929
22
7
76
973
10
0
88
980
26
6
71
974
43
57
53
913
27
119
56
760
Inpatient Hospital
21 [8717]
-2.0e-02
7.4e-01
3.2e+00
1.0e+50
3.3e+00
2.2e+00
8.6e-01
cases:28.57%
controls:28.98%
cases:18.37%
controls:9.69%
cases:25.51%
controls:1.33%
cases:10.20%
controls:0.00%
cases:28.87%
controls:1.43%
cases:46.88%
controls:8.97%
cases:37.35%
controls:20.14%
28
284
70
696
18
95
80
885
25
13
73
967
10
0
88
980
28
14
69
966
45
87
51
883
31
177
52
702
General Surgery
2 [38004447]
3.0e-01
1.4e+00
—
—
3.6e+00
2.0e+00
1.3e+00
cases:22.45%
controls:17.65%
cases:16.33%
controls:4.59%
—
—
—
—
cases:15.46%
controls:0.51%
cases:28.13%
controls:5.15%
cases:37.35%
controls:13.54%
22
173
76
807
16
45
82
935
—
—
15
5
82
975
27
50
69
920
31
119
52
760
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
1.9e-01
1.7e-01
2.5e+00
—
2.7e+00
1.6e+00
3.8e-01
cases:10.20%
controls:8.57%
cases:6.12%
controls:5.20%
cases:8.16%
controls:0.71%
—
—
cases:8.25%
controls:0.61%
cases:18.75%
controls:4.33%
cases:20.48%
controls:15.02%
10
84
88
896
6
51
92
929
8
7
90
973
—
8
6
89
974
18
42
78
928
17
132
66
747
Emergency Room Visit
ER [9203]
1.3e-01
8.5e-01
2.4e+00
—
2.0e+00
1.5e+00
7.6e-01
cases:31.63%
controls:28.98%
cases:20.41%
controls:9.90%
cases:11.22%
controls:1.12%
—
—
cases:7.22%
controls:1.02%
cases:32.29%
controls:9.28%
cases:38.55%
controls:22.75%
31
284
67
696
20
97
78
883
11
11
87
969
—
7
10
90
970
31
90
65
880
32
200
51
679
Blood group antibody screen [Presence] in Serum or Plasma
890-4 [3001079]
4.4e-01
1.5e+00
3.6e+00
1.0e+50
—
2.1e+00
8.7e-01
cases:9.18%
controls:6.12%
cases:8.16%
controls:1.94%
cases:15.31%
controls:0.51%
cases:6.12%
controls:0.00%
—
—
cases:19.79%
controls:2.99%
cases:19.28%
controls:9.10%
9
60
89
920
8
19
90
961
15
5
83
975
6
0
92
980
—
19
29
77
941
16
80
67
799
Tissue Pathology biopsy report
66121-5 [40768804]
9.7e-01
1.9e+00
—
1.0e+50
—
2.5e+00
1.1e+00
cases:11.22%
controls:4.59%
cases:7.14%
controls:1.12%
—
—
cases:15.31%
controls:0.00%
—
—
cases:16.67%
controls:1.65%
cases:15.66%
controls:5.57%
11
45
87
935
7
11
91
969
—
15
0
83
980
—
16
16
80
954
13
49
70
830
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
8.5e-02
3.0e-01
2.2e+00
—
2.4e+00
7.9e-01
2.5e-01
cases:29.59%
controls:27.86%
cases:30.61%
controls:24.59%
cases:26.53%
controls:3.78%
—
—
cases:29.90%
controls:3.78%
cases:41.67%
controls:24.54%
cases:48.19%
controls:41.98%
29
273
69
707
30
241
68
739
26
37
72
943
—
29
37
68
943
40
238
56
732
40
369
43
510
General anesthesia, balanced
WX408 [2001310808]
6.8e-01
—
1.0e+50
1.0e+50
1.0e+50
3.5e+00
1.9e+00
cases:5.10%
controls:2.65%
—
—
cases:7.14%
controls:0.00%
cases:8.16%
controls:0.00%
cases:7.22%
controls:0.00%
cases:16.67%
controls:0.62%
cases:10.84%
controls:1.82%
5
26
93
954
—
7
0
91
980
8
0
90
980
7
0
90
980
16
6
80
964
9
16
74
863
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
2.4e-01
5.7e-01
2.4e+00
1.0e+50
2.9e+00
7.7e-01
3.9e-01
cases:20.41%
controls:16.73%
cases:24.49%
controls:15.51%
cases:19.39%
controls:2.04%
cases:5.10%
controls:0.00%
cases:23.71%
controls:1.73%
cases:30.21%
controls:16.70%
cases:43.37%
controls:34.13%
20
164
78
816
24
152
74
828
19
20
79
960
5
0
93
980
23
17
74
963
29
162
67
808
36
300
47
579
C reactive protein [Mass/volume] in Serum or Plasma
1988-5 [3020460]
-3.5e-02
3.7e-01
1.6e+00
—
2.3e+00
1.2e+00
3.7e-01
cases:22.45%
controls:23.06%
cases:20.41%
controls:15.00%
cases:13.27%
controls:2.86%
—
—
cases:20.62%
controls:2.55%
cases:36.46%
controls:15.05%
cases:40.96%
controls:32.31%
22
226
76
754
20
147
78
833
13
28
85
952
—
20
25
77
955
35
146
61
824
34
284
49
595
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
1.1e-01
2.1e-01
2.4e+00
—
2.5e+00
7.3e-01
2.2e-01
cases:27.55%
controls:25.41%
cases:25.51%
controls:21.73%
cases:25.51%
controls:3.06%
—
—
cases:26.80%
controls:2.96%
cases:35.42%
controls:20.93%
cases:44.58%
controls:39.14%
27
249
71
731
25
213
73
767
25
30
73
950
—
26
29
71
951
34
203
62
767
37
344
46
535
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
8.9e-02
2.0e-01
2.4e+00
—
2.5e+00
7.0e-01
2.0e-01
cases:27.55%
controls:25.82%
cases:25.51%
controls:21.94%
cases:25.51%
controls:3.06%
—
—
cases:26.80%
controls:2.96%
cases:35.42%
controls:21.34%
cases:44.58%
controls:39.82%
27
253
71
727
25
215
73
765
25
30
73
950
—
26
29
71
951
34
207
62
763
37
350
46
529
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
1.9e-01
6.2e-01
—
—
2.4e+00
1.4e+00
9.9e-01
cases:8.16%
controls:6.84%
cases:7.14%
controls:3.98%
—
—
—
—
cases:6.19%
controls:0.61%
cases:15.63%
controls:4.23%
cases:24.10%
controls:10.58%
8
67
90
913
7
39
91
941
—
—
6
6
91
974
15
41
81
929
20
93
63
786
Thorax X-ray examination
GD1AA [2001303617]
1.3e-01
—
—
—
—
2.8e+00
2.0e+00
cases:7.14%
controls:6.33%
—
—
—
—
—
—
—
—
cases:26.04%
controls:2.06%
cases:32.53%
controls:6.37%
7
62
91
918
—
—
—
—
25
20
71
950
27
56
56
823
More than one and less than three hours
ZXE10 [2001311401]
4.4e-01
—
—
—
—
2.9e+00
1.6e+00
cases:8.16%
controls:5.41%
—
—
—
—
—
—
—
—
cases:13.54%
controls:0.82%
cases:10.84%
controls:2.28%
8
53
90
927
—
—
—
—
13
8
83
962
9
20
74
859
Physiotherapy
R4110 [2001310233]
—
-1.0e+50
—
1.0e+50
1.0e+50
2.8e+00
1.8e+00
—
—
cases:0.00%
controls:0.51%
—
—
cases:8.16%
controls:0.00%
cases:7.22%
controls:0.00%
cases:18.75%
controls:1.44%
cases:15.66%
controls:2.96%
—
0
5
98
975
—
8
0
90
980
7
0
90
980
18
14
78
956
13
26
70
853
Scheduled procedure
ZXD10 [2001311387]
5.0e-01
—
—
1.0e+50
—
2.7e+00
1.8e+00
cases:8.16%
controls:5.10%
—
—
—
—
cases:7.14%
controls:0.00%
—
—
cases:18.75%
controls:1.55%
cases:14.46%
controls:2.62%
8
50
90
930
—
—
7
0
91
980
—
18
15
78
955
12
23
71
856
CBC panel - Blood by Automated count
58410-2 [40761511]
2.2e-01
6.4e-02
2.0e+00
—
2.5e+00
6.3e-01
7.2e-02
cases:29.59%
controls:25.20%
cases:20.41%
controls:19.39%
cases:19.39%
controls:3.06%
—
—
cases:21.65%
controls:2.24%
cases:29.17%
controls:18.04%
cases:38.55%
controls:36.86%
29
247
69
733
20
190
78
790
19
30
79
950
—
21
22
76
958
28
175
68
795
32
324
51
555
Erythrocyte [DistWidth] in Red Blood Cells
30385-9 [3002385]
1.1e-01
1.3e-01
2.0e+00
—
2.5e+00
7.0e-01
3.7e-01
cases:21.43%
controls:19.59%
cases:17.35%
controls:15.51%
cases:18.37%
controls:2.96%
—
—
cases:24.74%
controls:2.65%
cases:29.17%
controls:16.91%
cases:42.17%
controls:33.45%
21
192
77
788
17
152
81
828
18
29
80
951
—
24
26
73
954
28
164
68
806
35
294
48
585
oxycodone; oral, parenteral
N02AA05 [21604260]
—
-1.0e+50
—
—
—
2.5e+00
1.8e+00
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:6.25%
controls:0.52%
cases:8.43%
controls:1.48%
—
0
7
98
973
—
—
—
6
5
90
965
7
13
76
866
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
-6.0e-02
6.3e-01
—
—
2.9e+00
1.4e+00
8.5e-01
cases:7.14%
controls:7.55%
cases:6.12%
controls:3.37%
—
—
—
—
cases:8.25%
controls:0.51%
cases:14.58%
controls:3.92%
cases:22.89%
controls:11.26%
7
74
91
906
6
33
92
947
—
—
8
5
89
975
14
38
82
932
19
99
64
780
pregabalin; oral
N02BF02 [955152]
—
—
—
—
—
2.5e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:11.46%
controls:1.03%
cases:15.66%
controls:3.07%
—
—
—
—
—
11
10
85
960
13
27
70
852
MCHC [Entitic Mass/volume] in Red Blood Cells
28540-3 [3003338]
-7.2e-02
5.8e-02
1.9e+00
—
2.1e+00
5.2e-01
2.2e-01
cases:23.47%
controls:24.80%
cases:20.41%
controls:19.49%
cases:19.39%
controls:3.37%
—
—
cases:23.71%
controls:3.67%
cases:29.17%
controls:19.69%
cases:39.76%
controls:34.70%
23
243
75
737
20
191
78
789
19
33
79
947
—
23
36
74
944
28
191
68
779
33
305
50
574
Platelets [#/volume] in Blood
26515-7 [3007461]
2.8e-02
2.8e-01
1.9e+00
—
2.1e+00
6.3e-01
2.0e-01
cases:31.63%
controls:31.02%
cases:32.65%
controls:26.73%
cases:24.49%
controls:4.59%
—
—
cases:28.87%
controls:4.69%
cases:40.63%
controls:26.80%
cases:50.60%
controls:45.73%
31
304
67
676
32
262
66
718
24
45
74
935
—
28
46
69
934
39
260
57
710
42
402
41
477
MCV [Entitic mean volume] in Red Blood Cells
30428-7 [3024731]
1.9e-02
2.8e-01
1.9e+00
—
2.1e+00
6.1e-01
2.0e-01
cases:31.63%
controls:31.22%
cases:32.65%
controls:26.84%
cases:24.49%
controls:4.59%
—
—
cases:28.87%
controls:4.80%
cases:40.63%
controls:27.01%
cases:50.60%
controls:45.73%
31
306
67
674
32
263
66
717
24
45
74
935
—
28
47
69
933
39
262
57
708
42
402
41
477
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
1.9e-02
2.7e-01
1.9e+00
—
2.1e+00
6.1e-01
2.0e-01
cases:31.63%
controls:31.22%
cases:32.65%
controls:26.94%
cases:24.49%
controls:4.59%
—
—
cases:28.87%
controls:4.80%
cases:40.63%
controls:27.01%
cases:50.60%
controls:45.73%
31
306
67
674
32
264
66
716
24
45
74
935
—
28
47
69
933
39
262
57
708
42
402
41
477
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
1.9e-02
2.8e-01
1.9e+00
—
2.1e+00
6.1e-01
2.0e-01
cases:31.63%
controls:31.22%
cases:32.65%
controls:26.84%
cases:24.49%
controls:4.59%
—
—
cases:28.87%
controls:4.80%
cases:40.63%
controls:27.11%
cases:50.60%
controls:45.73%
31
306
67
674
32
263
66
717
24
45
74
935
—
28
47
69
933
39
263
57
707
42
402
41
477
MCH [Entitic mass]
28539-5 [3035941]
1.9e-02
2.8e-01
1.9e+00
—
2.1e+00
6.1e-01
2.0e-01
cases:31.63%
controls:31.22%
cases:32.65%
controls:26.84%
cases:24.49%
controls:4.59%
—
—
cases:28.87%
controls:4.80%
cases:40.63%
controls:27.01%
cases:50.60%
controls:45.73%
31
306
67
674
32
263
66
717
24
45
74
935
—
28
47
69
933
39
262
57
708
42
402
41
477
Leukocytes [#/volume] in Blood
26464-8 [3010813]
1.4e-02
2.8e-01
1.9e+00
—
2.1e+00
6.1e-01
2.0e-01
cases:31.63%
controls:31.33%
cases:32.65%
controls:26.84%
cases:24.49%
controls:4.59%
—
—
cases:28.87%
controls:4.80%
cases:40.63%
controls:27.01%
cases:50.60%
controls:45.73%
31
307
67
673
32
263
66
717
24
45
74
935
—
28
47
69
933
39
262
57
708
42
402
41
477
Erythrocytes [#/volume] in Blood
26453-1 [3026361]
1.9e-02
2.8e-01
1.9e+00
—
2.1e+00
6.1e-01
2.0e-01
cases:31.63%
controls:31.22%
cases:32.65%
controls:26.84%
cases:24.49%
controls:4.59%
—
—
cases:28.87%
controls:4.80%
cases:40.63%
controls:27.11%
cases:50.60%
controls:45.73%
31
306
67
674
32
263
66
717
24
45
74
935
—
28
47
69
933
39
263
57
707
42
402
41
477
INR in Blood by Coagulation assay
34714-6 [3032080]
3.2e-01
6.2e-01
2.3e+00
—
1.4e+00
1.6e+00
5.3e-01
cases:9.18%
controls:6.84%
cases:7.14%
controls:3.98%
cases:11.22%
controls:1.22%
—
—
cases:6.19%
controls:1.53%
cases:17.71%
controls:4.33%
cases:18.07%
controls:11.49%
9
67
89
913
7
39
91
941
11
12
87
968
—
6
15
91
965
17
42
79
928
15
101
68
778
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
-3.5e-01
1.8e-02
1.0e+00
—
2.6e+00
1.1e+00
5.4e-01
cases:20.41%
controls:26.73%
cases:13.27%
controls:13.06%
cases:7.14%
controls:2.65%
—
—
cases:22.68%
controls:2.04%
cases:34.38%
controls:14.74%
cases:44.58%
controls:31.85%
20
262
78
718
13
128
85
852
7
26
91
954
—
22
20
75
960
33
143
63
827
37
280
46
599
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
—
—
—
1.0e+50
—
2.2e+00
1.4e+00
—
—
—
—
—
—
cases:5.10%
controls:0.00%
—
—
cases:15.63%
controls:1.96%
cases:14.46%
controls:3.87%
—
—
—
5
0
93
980
—
15
19
81
951
12
34
71
845
Pulmonary Disease
29 [38004472]
—
1.4e+00
2.3e+00
—
—
9.9e-02
5.0e-02
—
—
cases:11.22%
controls:3.16%
cases:8.16%
controls:0.92%
—
—
—
—
cases:5.21%
controls:4.74%
cases:9.64%
controls:9.22%
—
11
31
87
949
8
9
90
971
—
—
5
46
91
924
8
81
75
798
Infiltration anesthesia
WX110 [2001310767]
2.8e-01
7.4e-01
2.5e+00
—
—
1.1e+00
4.6e-01
cases:19.39%
controls:15.41%
cases:9.18%
controls:4.59%
cases:7.14%
controls:0.61%
—
—
—
—
cases:15.63%
controls:5.88%
cases:22.89%
controls:15.81%
19
151
79
829
9
45
89
935
7
6
91
974
—
—
15
57
81
913
19
139
64
740
Emergency Medicine
93 [38004510]
-1.6e-01
5.2e-01
2.3e+00
—
—
1.3e+00
3.8e-01
cases:8.16%
controls:9.49%
cases:10.20%
controls:6.33%
cases:5.10%
controls:0.51%
—
—
—
—
cases:16.67%
controls:5.36%
cases:26.51%
controls:19.80%
8
93
90
887
10
62
88
918
5
5
93
975
—
—
16
52
80
918
22
174
61
705
Blood type and Crossmatch panel - Blood
34531-4 [3044640]
8.9e-01
1.5e+00
—
1.0e+50
—
2.2e+00
1.3e+00
cases:9.18%
controls:3.98%
cases:6.12%
controls:1.43%
—
—
cases:6.12%
controls:0.00%
—
—
cases:18.75%
controls:2.37%
cases:16.87%
controls:5.01%
9
39
89
941
6
14
92
966
—
6
0
92
980
—
18
23
78
947
14
44
69
835
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
2.6e-01
7.6e-02
2.2e+00
—
1.8e+00
1.1e+00
7.3e-01
cases:17.35%
controls:13.88%
cases:9.18%
controls:8.57%
cases:9.18%
controls:1.12%
—
—
cases:7.22%
controls:1.33%
cases:20.83%
controls:7.73%
cases:36.14%
controls:21.39%
17
136
81
844
9
84
89
896
9
11
89
969
—
7
13
90
967
20
75
76
895
30
188
53
691
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
1.3e-01
8.9e-03
1.3e+00
—
2.1e+00
1.2e+00
5.7e-01
cases:31.63%
controls:28.98%
cases:13.27%
controls:13.16%
cases:7.14%
controls:2.14%
—
—
cases:15.46%
controls:2.14%
cases:32.29%
controls:12.78%
cases:40.96%
controls:28.21%
31
284
67
696
13
129
85
851
7
21
91
959
—
15
21
82
959
31
124
65
846
34
248
49
631
ibuprofen
R02AX02 [1588667]
1.3e-01
8.9e-03
1.3e+00
—
2.1e+00
1.2e+00
5.7e-01
cases:31.63%
controls:28.98%
cases:13.27%
controls:13.16%
cases:7.14%
controls:2.14%
—
—
cases:15.46%
controls:2.14%
cases:32.29%
controls:12.78%
cases:40.96%
controls:28.21%
31
284
67
696
13
129
85
851
7
21
91
959
—
15
21
82
959
31
124
65
846
34
248
49
631
Laboratory Visit
OMOP4822461 [32036]
3.1e-02
3.9e-01
1.6e+00
—
1.7e+00
4.9e-01
9.3e-02
cases:35.71%
controls:35.00%
cases:41.84%
controls:32.65%
cases:31.63%
controls:8.88%
—
—
cases:35.05%
controls:9.39%
cases:47.92%
controls:36.08%
cases:51.81%
controls:49.49%
35
343
63
637
41
320
57
660
31
87
67
893
—
34
92
63
888
46
350
50
620
43
435
40
444
Calcium [Moles/volume] in Serum or Plasma
2000-8 [3015377]
—
—
—
—
—
1.8e+00
1.3e+00
—
—
—
—
—
—
—
—
—
—
cases:7.29%
controls:1.24%
cases:16.87%
controls:5.23%
—
—
—
—
—
7
12
89
958
14
46
69
833
Otolaryngology
4 [38004449]
7.3e-01
1.2e+00
—
1.0e+50
—
1.8e+00
1.2e+00
cases:14.29%
controls:7.45%
cases:12.24%
controls:3.98%
—
—
cases:7.14%
controls:0.00%
—
—
cases:20.83%
controls:4.02%
cases:27.71%
controls:9.90%
14
73
84
907
12
39
86
941
—
7
0
91
980
—
20
39
76
931
23
87
60
792
enoxaparin; parenteral
B01AB05 [21600976]
4.3e-01
—
—
—
—
3.0e+00
1.4e+00
cases:6.12%
controls:4.08%
—
—
—
—
—
—
—
—
cases:11.46%
controls:0.62%
cases:10.84%
controls:2.96%
6
40
92
940
—
—
—
—
11
6
85
964
9
26
74
853
Plastic And Reconstructive Surgery
24 [38004467]
—
2.0e+00
—
—
1.0e+50
—
3.0e+00
—
—
cases:5.10%
controls:0.71%
—
—
—
—
cases:7.22%
controls:0.00%
—
—
cases:12.05%
controls:0.68%
—
5
7
93
973
—
—
7
0
90
980
—
10
6
73
873
Thoracic and Cardiac Surgery
OMOP4822009 [45756830]
—
—
—
—
—
2.7e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:7.29%
controls:0.52%
cases:6.02%
controls:0.80%
—
—
—
—
—
7
5
89
965
5
7
78
872
pH of Arterial blood
2744-1 [3019977]
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.52%
—
—
—
—
—
—
—
6
5
90
965
—
Left side
ZXA05 [2001311347]
5.7e-01
-1.0e+50
—
—
—
2.5e+00
1.0e+00
cases:5.10%
controls:2.96%
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:8.33%
controls:0.72%
cases:6.02%
controls:2.28%
5
29
93
951
0
7
98
973
—
—
—
8
7
88
963
5
20
78
859
12 lead EKG panel
34534-8 [3044889]
1.8e-01
4.4e-01
2.5e+00
—
—
7.7e-01
4.7e-01
cases:14.29%
controls:12.24%
cases:12.24%
controls:8.27%
cases:14.29%
controls:1.33%
—
—
—
—
cases:16.67%
controls:8.45%
cases:30.12%
controls:21.16%
14
120
84
860
12
81
86
899
14
13
84
967
—
—
16
82
80
888
25
186
58
693
Office Visit
OMOP4822458 [581477]
—
—
—
—
—
2.4e+00
1.2e+00
—
—
—
—
—
—
—
—
—
—
cases:16.67%
controls:1.75%
cases:13.25%
controls:4.55%
—
—
—
—
—
16
17
80
953
11
40
72
839
Base excess in Arterial blood by calculation
1925-7 [3003396]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.62%
—
—
—
—
—
—
—
6
6
90
964
—
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.62%
—
—
—
—
—
—
—
6
6
90
964
—
tinzaparin; parenteral
B01AB10 [21600981]
—
—
—
—
1.0e+50
2.4e+00
1.8e+00
—
—
—
—
—
—
—
—
cases:6.19%
controls:0.00%
cases:6.25%
controls:0.62%
cases:7.23%
controls:1.25%
—
—
—
—
6
0
91
980
6
6
90
964
6
11
77
868
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
—
—
—
—
—
2.4e+00
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.62%
—
—
—
—
—
—
—
6
6
90
964
—
Thorax X-ray examination outside radiological department
GD1UA [2001303652]
—
—
—
—
—
2.4e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:5.21%
controls:0.52%
cases:6.02%
controls:2.16%
—
—
—
—
—
5
5
91
965
5
19
78
860
Microorganisms panel - Urine sediment
58435-9 [40761536]
—
—
—
—
—
2.4e+00
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:5.21%
controls:0.52%
cases:6.02%
controls:0.80%
—
—
—
—
—
5
5
91
965
5
7
78
872
sulfasalazine; oral, rectal
A07EC01 [21600663]
1.9e+00
2.3e+00
—
—
—
—
—
cases:5.10%
controls:0.82%
cases:5.10%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
5
8
93
972
5
5
93
975
—
—
—
—
—
Other specified special examinations
Z01.8 [45581003]
-1.0e+50
2.3e+00
—
—
—
—
—
cases:0.00%
controls:2.04%
cases:5.10%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
0
20
98
960
5
5
93
975
—
—
—
—
—
Inpatient Visit
IP [9201]
3.6e-01
—
—
1.0e+50
—
2.3e+00
8.8e-01
cases:10.20%
controls:7.35%
—
—
—
—
cases:6.12%
controls:0.00%
—
—
cases:21.88%
controls:2.78%
cases:19.28%
controls:8.99%
10
72
88
908
—
—
6
0
92
980
—
21
27
75
943
16
79
67
800
Intravenous general anesthesia
WX404 [2001310807]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:0.80%
—
—
—
—
—
—
6
7
77
872
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
-1.0e+50
-1.0e+50
—
—
—
2.2e+00
6.7e-01
cases:0.00%
controls:1.53%
cases:0.00%
controls:0.92%
—
—
—
—
—
—
cases:6.25%
controls:0.72%
cases:6.02%
controls:3.19%
0
15
98
965
0
9
98
971
—
—
—
6
7
90
963
5
28
78
851
Limited function/disability (L)
L28 [2002000647]
—
—
—
—
—
2.2e+00
1.0e+00
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.72%
cases:6.02%
controls:2.28%
—
—
—
—
—
6
7
90
963
5
20
78
859
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
—
—
—
—
—
2.1e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.82%
cases:8.43%
controls:2.84%
—
—
—
—
—
6
8
90
962
7
25
76
854
One hour or less
ZXE00 [2001311394]
4.8e-01
—
—
—
—
2.1e+00
1.4e+00
cases:8.16%
controls:5.20%
—
—
—
—
—
—
—
—
cases:10.42%
controls:1.44%
cases:10.84%
controls:2.84%
8
51
90
929
—
—
—
—
10
14
86
956
9
25
74
854
Medical doctor
Z2221 [2001311556]
3.7e-01
—
—
—
—
2.1e+00
1.4e+00
cases:5.10%
controls:3.57%
—
—
—
—
—
—
—
—
cases:8.33%
controls:1.13%
cases:6.02%
controls:1.59%
5
35
93
945
—
—
—
—
8
11
88
959
5
14
78
865
Prothrombin time (PT) actual/Normal
5894-1 [3033658]
7.6e-01
1.5e+00
—
1.0e+50
—
2.0e+00
1.0e+00
cases:6.12%
controls:2.96%
cases:6.12%
controls:1.43%
—
—
cases:5.10%
controls:0.00%
—
—
cases:14.58%
controls:2.16%
cases:15.66%
controls:6.37%
6
29
92
951
6
14
92
966
—
5
0
93
980
—
14
21
82
949
13
56
70
823
Case Management Agency
251B00000X [38004193]
-1.2e-01
8.3e-03
9.1e-01
—
1.0e+00
3.2e-01
-1.4e-01
cases:55.10%
controls:57.96%
cases:44.90%
controls:44.69%
cases:34.69%
controls:17.65%
—
—
cases:35.05%
controls:16.43%
cases:55.21%
controls:47.32%
cases:59.04%
controls:62.34%
54
568
44
412
44
438
54
542
34
173
64
807
—
34
161
63
819
53
459
43
511
49
548
34
331
General anaesthesia
WX402 [2001310806]
—
—
—
1.0e+50
—
—
1.8e+00
—
—
—
—
—
—
cases:5.10%
controls:0.00%
—
—
—
—
cases:13.25%
controls:2.39%
—
—
—
5
0
93
980
—
—
11
21
72
858
Treatment plan or consultation
WZC00 [2001310885]
9.1e-01
—
—
—
—
1.8e+00
1.1e+00
cases:6.12%
controls:2.55%
—
—
—
—
—
—
—
—
cases:9.38%
controls:1.65%
cases:9.64%
controls:3.53%
6
25
92
955
—
—
—
—
9
16
87
954
8
31
75
848
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
—
6.4e-01
—
—
—
1.8e+00
8.4e-01
—
—
cases:5.10%
controls:2.76%
—
—
—
—
—
—
cases:12.50%
controls:2.37%
cases:14.46%
controls:6.83%
—
5
27
93
953
—
—
—
12
23
84
947
12
60
71
819
cefalexin; oral
J01DB01 [21602870]
2.0e-01
—
—
—
1.8e+00
5.8e-01
4.4e-01
cases:26.53%
controls:22.76%
—
—
—
—
—
—
cases:10.31%
controls:1.94%
cases:12.50%
controls:7.42%
cases:31.33%
controls:22.64%
26
223
72
757
—
—
—
10
19
87
961
12
72
84
898
26
199
57
680
ketoprofen; oral, parenteral, rectal
M01AE03 [21603969]
7.0e-01
1.6e+00
—
—
—
1.8e+00
8.3e-01
cases:7.14%
controls:3.67%
cases:6.12%
controls:1.33%
—
—
—
—
—
—
cases:8.33%
controls:1.55%
cases:9.64%
controls:4.44%
7
36
91
944
6
13
92
967
—
—
—
8
15
88
955
8
39
75
840
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:10.84%
controls:2.16%
—
—
—
—
—
—
9
19
74
860
dexamethasone; oral, parenteral
H02AB02 [21602730]
—
—
—
—
—
—
1.7e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.64%
controls:1.93%
—
—
—
—
—
—
8
17
75
862
Bacteria identified in Blood by Culture
600-7 [3023368]
—
—
—
—
—
1.6e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:9.38%
controls:2.06%
cases:12.05%
controls:4.55%
—
—
—
—
—
9
20
87
950
10
40
73
839
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1.6e-01
6.4e-01
—
—
2.0e+00
1.4e+00
9.6e-01
cases:7.14%
controls:6.12%
cases:7.14%
controls:3.88%
—
—
—
—
cases:5.15%
controls:0.71%
cases:12.50%
controls:3.51%
cases:20.48%
controls:8.99%
7
60
91
920
7
38
91
942
—
—
5
7
92
973
12
34
84
936
17
79
66
800
Pharmacy visit
OMOP4822462 [581458]
1.6e-01
2.5e-01
3.9e-01
1.2e+00
9.5e-01
9.0e-01
4.1e-02
cases:85.71%
controls:83.67%
cases:81.63%
controls:77.65%
cases:52.04%
controls:42.35%
cases:6.12%
controls:1.84%
cases:64.95%
controls:41.63%
cases:90.63%
controls:79.69%
cases:91.57%
controls:91.24%
84
820
14
160
80
761
18
219
51
415
47
565
6
18
92
962
63
408
34
572
87
773
9
197
76
802
7
77
Internal Medicine
11 [38004456]
-7.3e-02
2.9e-01
—
—
—
4.4e-01
9.0e-01
cases:18.37%
controls:19.49%
cases:11.22%
controls:8.67%
—
—
—
—
—
—
cases:12.50%
controls:8.45%
cases:36.14%
controls:18.77%
18
191
80
789
11
85
87
895
—
—
—
12
82
84
888
30
165
53
714
Neutrophils [#/volume] in Blood by Automated count
751-8 [3013650]
4.4e-01
8.6e-01
1.7e+00
—
1.8e+00
7.6e-01
8.9e-01
cases:13.27%
controls:8.98%
cases:11.22%
controls:5.10%
cases:6.12%
controls:1.12%
—
—
cases:6.19%
controls:1.12%
cases:13.54%
controls:6.80%
cases:28.92%
controls:14.33%
13
88
85
892
11
50
87
930
6
11
92
969
—
6
11
91
969
13
66
83
904
24
126
59
753
Hemoglobin [Mass/volume] in Venous blood
30350-3 [3004119]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
cases:0.00%
controls:1.48%
—
—
—
—
—
0
7
96
963
0
13
83
866
Type 1 diabetes mellitus, With multiple complications
E10.7 [45571655]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
0
5
98
975
—
—
—
0
5
96
965
—
sulfamethoxazole and trimethoprim
J01EE01 [21602961]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
98
975
—
—
—
—
—
—
Glaucoma suspect
H40.0 [45567051]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
0
9
98
971
—
—
—
—
—
0
8
83
871
cefaclor; oral
J01DC04 [21602886]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
98
975
—
—
—
—
—
—
Fracture of neck of femur
S72.0 [45593656]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
7
83
872
Periodontal treatment
SDA03 [2001310328]
-8.1e-02
—
—
—
—
—
6.3e-01
cases:5.10%
controls:5.51%
—
—
—
—
—
—
—
—
—
—
cases:15.66%
controls:8.99%
5
54
93
926
—
—
—
—
—
13
79
70
800
Persons encountering health services in other specified circumstances
Z76.8 [45542457]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
betamethasone
D07AC01 [21602120]
2.4e-01
—
—
—
—
-1.0e+50
4.1e-01
cases:8.16%
controls:6.53%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.99%
cases:9.64%
controls:6.60%
8
64
90
916
—
—
—
—
0
29
96
941
8
58
75
821
Intravenous administration of medicine
SPAT1255 [2001700356]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.71%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
0
7
98
973
0
5
98
975
—
—
—
—
—
citalopram; oral, parenteral
N06AB04 [21604712]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
0
6
98
974
—
0
7
97
973
—
—
amoxicillin and beta-lactamase inhibitor; oral, parenteral
J01CR02 [21602863]
-3.4e-01
—
—
—
—
1.4e+00
3.8e-01
cases:5.10%
controls:7.04%
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.65%
cases:8.43%
controls:5.92%
5
69
93
911
—
—
—
—
6
16
90
954
7
52
76
827
omeprazole; oral, parenteral
A02BC01 [21600096]
4.8e-01
—
-1.0e+50
—
-1.0e+50
—
—
cases:6.12%
controls:3.88%
—
—
cases:0.00%
controls:0.71%
—
—
cases:0.00%
controls:0.51%
—
—
—
—
6
38
92
942
—
0
7
98
973
—
0
5
97
975
—
—
Tooth plaque
K03.66 [2000502691]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
0
5
98
975
—
—
—
—
0
5
96
965
—
Blepharochalasis
H02.3 [45586340]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
Old myocardial infarction
I25.2 [45601025]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
98
971
—
—
—
—
—
—
Leukocytes [Presence] in Urine
33052-2 [3045414]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
6
96
964
—
ketoprofen; ointment
M02AA10 [21604046]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
0
5
96
965
—
Radiotherapy of metastasis
WF049 [2001310705]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:0.00%
—
—
—
—
—
—
5
0
78
879
Risk factor cardiovascular disease
K22 [2002000551]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
98
970
—
—
—
—
—
—
diphenhydramine, combinations
R06AA52 [21603454]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
0
6
98
974
—
—
—
0
5
96
965
—
aciclovir; oral, parenteral
J05AB01 [21603131]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
0
10
98
970
—
—
—
—
—
Emergency Room and Inpatient Visit
ERIP [262]
—
—
—
—
—
9.6e-01
9.2e-01
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:2.47%
cases:18.07%
controls:8.08%
—
—
—
—
—
6
24
90
946
15
71
68
808
oseltamivir; oral
J05AH02 [21603179]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
7
98
973
—
—
—
—
—
0
6
83
873
Standard MRI examination of brain with high intensity magnet
AA1BG [2001300112]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
0
9
83
870
Percutaneous insertion of coronary artery stent
FN1YT [2001303064]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
0
7
98
973
—
—
—
—
—
0
8
83
871
ECG with 12 standard connections
XF400 [2001303368]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
—
—
—
—
—
0
6
96
964
—
First trimester maternal screen panel - Serum or Plasma
48798-3 [3050129]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:1.84%
—
—
—
—
—
—
—
—
—
—
—
0
18
98
962
—
—
—
—
—
Counselling and guidance related to physical exercise
SPAT1305 [2001700406]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
98
972
—
—
—
—
—
—
Personal history of diseases of the digestive system
Z87.1 [45542474]
2.2e-01
6.8e-01
—
—
-1.0e+50
7.1e-01
6.1e-01
cases:10.20%
controls:8.37%
cases:5.10%
controls:2.65%
—
—
—
—
cases:0.00%
controls:0.51%
cases:7.29%
controls:3.71%
cases:12.05%
controls:6.94%
10
82
88
898
5
26
93
954
—
—
0
5
97
975
7
36
89
934
10
61
73
818
Other and unspecified skin changes
R23.8 [45573020]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
6
98
974
—
—
—
—
—
pH of Urine
2756-5 [3015736]
—
—
—
—
—
6.1e-01
4.7e-01
—
—
—
—
—
—
—
—
—
—
cases:5.21%
controls:2.89%
cases:14.46%
controls:9.56%
—
—
—
—
—
5
28
91
942
12
84
71
795
betamethasone
C05AA05 [21601610]
2.4e-01
—
—
—
—
-1.0e+50
4.1e-01
cases:8.16%
controls:6.53%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.99%
cases:9.64%
controls:6.60%
8
64
90
916
—
—
—
—
0
29
96
941
8
58
75
821
Paranasal sinuses X-ray examination in one projection
DM1QA [2001301761]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
98
971
—
—
—
—
—
—
Surface analgesia on skin or mucosa
WX105 [2001310765]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
0
6
98
974
—
—
—
—
—
0
10
83
869
Gonarthrosis, unspecified
M17.9 [45606128]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.48%
0
10
98
970
—
—
—
—
—
0
13
83
866
Wheezing
R06.2 [45548946]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
98
973
—
—
—
—
—
—
Other primary coxarthrosis
M16.1 [45591741]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
0
10
83
869
Presence of intraocular lens
Z96.1 [45585885]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
0
7
98
973
—
—
—
—
0
5
96
965
—
Other sleep disorders
G47.8 [45581501]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
azithromycin; oral, parenteral
J01FA10 [21602978]
2.8e-02
—
—
—
—
—
4.5e-01
cases:8.16%
controls:7.96%
—
—
—
—
—
—
—
—
—
—
cases:9.64%
controls:6.37%
8
78
90
902
—
—
—
—
—
8
56
75
823
Unspecified fall
W19 [45756257]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
7
83
872
Chest pain NOS
A11 [2002000152]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.93%
0
8
98
972
—
—
—
—
—
0
17
83
862
Angiography of the heart and coronary arteries
81 [2002100125]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
98
972
—
—
—
—
—
—
Teeth/gum disease
D82 [2002000380]
-2.8e-01
—
—
—
—
—
—
cases:5.10%
controls:6.63%
—
—
—
—
—
—
—
—
—
—
—
—
5
65
93
915
—
—
—
—
—
—
Removal of sutures
SPAT1153 [2001700254]
5.4e-01
-1.0e+50
—
—
—
1.6e+00
6.7e-01
cases:6.12%
controls:3.67%
cases:0.00%
controls:0.92%
—
—
—
—
—
—
cases:5.21%
controls:1.13%
cases:6.02%
controls:3.19%
6
36
92
944
0
9
98
971
—
—
—
5
11
91
959
5
28
78
851
Release of median nerve
ACC51 [2001300642]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
0
9
98
971
—
—
—
—
—
0
5
83
874
Vaginal symptom/complaint other
X15 [2002001300]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
8
83
871
mometasone; nasal
R01AD09 [21605051]
3.5e-01
—
—
—
-1.0e+50
—
2.6e-01
cases:8.16%
controls:5.92%
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
cases:8.43%
controls:6.60%
8
58
90
922
—
—
—
0
6
97
974
—
7
58
76
821
Skin symptom/complaint other
S29 [2002000993]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
—
0
9
96
961
—
Oxygen [Partial pressure] in Venous blood
2705-2 [3024354]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
0
8
98
972
—
—
—
0
8
96
962
—
glyceryl trinitrate; local oral, oral, sublingual, transdermal
C01DA02 [21600317]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
0
7
98
973
—
—
—
—
prednisolone; oral, parenteral
H02AB06 [21602734]
1.9e-01
3.5e-01
—
—
-1.0e+50
3.1e-01
3.5e-01
cases:11.22%
controls:9.49%
cases:6.12%
controls:4.39%
—
—
—
—
cases:0.00%
controls:0.71%
cases:6.25%
controls:4.64%
cases:16.87%
controls:12.51%
11
93
87
887
6
43
92
937
—
—
0
7
97
973
6
45
90
925
14
110
69
769
Acute tubulo-interstitial nephritis
N10 [45543856]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
98
970
—
—
—
—
—
—
isosorbide mononitrate; oral
C01DA14 [21600324]
—
—
-1.0e+50
—
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
0
8
98
972
—
0
8
97
972
—
—
Glucose [Moles/volume] in Venous blood
39480-9 [3038515]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
Mouth breathing
R06.5 [45573006]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
0
9
83
870
Erysipelas
A46 [45561706]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
0
8
98
972
—
—
—
—
—
Benign paroxysmal vertigo
H81.1 [45572061]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
0
9
83
870
Chronic ischaemic heart disease
I25 [45581765]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
0
8
98
972
—
—
—
0
9
96
961
—
Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection
6357-8 [3024950]
—
—
—
—
—
—
8.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:2.73%
—
—
—
—
—
—
5
24
78
855
Opening and preparing the root canals, complicated
SGA03 [2001310381]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
0
10
83
869
Cholesterol in HDL [Moles/volume] in Serum or Plasma
14646-4 [3023602]
-4.6e-02
-1.7e-01
-1.0e+50
—
-1.0e+50
-1.1e+00
-2.9e-01
cases:22.45%
controls:23.27%
cases:13.27%
controls:15.31%
cases:0.00%
controls:2.04%
—
—
cases:0.00%
controls:1.73%
cases:6.25%
controls:16.80%
cases:30.12%
controls:36.52%
22
228
76
752
13
150
85
830
0
20
98
960
—
0
17
97
963
6
163
90
807
25
321
58
558
Nuclear Ab [Titer] in Serum
29953-7 [3037522]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:0.00%
controls:1.24%
—
—
—
0
7
98
973
—
—
—
0
12
96
958
—
Tacrine, donepezil, rivastigmine, galantamine and other major and expensive drugs used to treat Alzheimer's disease
307 [2001600266]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
0
5
98
975
—
—
—
—
—
0
7
83
872
estradiol; nasal, oral, parenteral, rectal, transdermal, vaginal
G03CA03 [21602517]
8.6e-01
7.2e-01
—
—
—
4.5e-01
1.6e-01
cases:22.45%
controls:10.92%
cases:13.27%
controls:6.94%
—
—
—
—
—
—
cases:11.46%
controls:7.63%
cases:18.07%
controls:15.81%
22
107
76
873
13
68
85
912
—
—
—
11
74
85
896
15
139
68
740
Red eye
F02 [2002000400]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
Type 2 diabetes mellitus, with renal complications
E11.2 [45605400]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
6
98
974
—
—
—
—
—
0
6
83
873
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
2.6e-01
2.6e-01
—
—
—
2.1e-01
5.4e-01
cases:9.18%
controls:7.24%
cases:9.18%
controls:7.24%
—
—
—
—
—
—
cases:9.38%
controls:7.73%
cases:13.25%
controls:8.19%
9
71
89
909
9
71
89
909
—
—
—
9
75
87
895
11
72
72
807
tizanidine; oral
M03BX02 [21604116]
-3.1e-01
—
—
—
—
—
-5.2e-01
cases:8.16%
controls:10.82%
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:11.60%
8
106
90
874
—
—
—
—
—
6
102
77
777
Moderate depressive episode
F32.1 [45552478]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
7
83
872
Local application of medicine to mouth
SXA20 [2001310579]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
98
974
—
—
—
—
—
—
Diabetes, insulin-treated
103 [2001600103]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.55%
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
0
25
98
955
0
7
98
973
—
—
—
0
6
96
964
—
hepatitis A, inactivated, whole virus
J07BC02 [21601339]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
0
5
98
975
0
5
98
975
—
—
—
—
—
Thyrotropin receptor Ab [Units/volume] in Serum
5385-0 [3017044]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
98
974
—
—
—
—
—
—
Pollen allergy UNS
J30.19 [2000502595]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
perindopril; oral
C09AA04 [21601788]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.22%
cases:0.00%
controls:0.82%
—
—
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:0.72%
cases:0.00%
controls:0.80%
0
12
98
968
0
8
98
972
—
—
0
5
97
975
0
7
96
963
0
7
83
872
Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma
33762-6 [3029187]
2.6e-01
—
—
—
—
—
3.4e-01
cases:5.10%
controls:3.98%
—
—
—
—
—
—
—
—
—
—
cases:9.64%
controls:7.05%
5
39
93
941
—
—
—
—
—
8
62
75
817
ispaghula (psylla seeds); oral
A06AC01 [21600555]
8.7e-01
—
—
—
—
7.7e-01
—
cases:8.16%
controls:3.57%
—
—
—
—
—
—
—
—
cases:5.21%
controls:2.47%
—
—
8
35
90
945
—
—
—
—
5
24
91
946
—
Celiac disease serology panel - Serum
94494-2 [36660697]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
0
6
98
974
—
—
—
—
—
liraglutide; parenteral
A10BJ02 [1123630]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
8
83
871
Chronic rhinitis
J31.0 [45572165]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
98
971
—
—
—
—
—
—
Fractures of other parts of lower leg
S82.8 [45536135]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
desloratadine; oral
R06AX27 [21603526]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:1.73%
—
—
—
—
—
—
cases:0.00%
controls:2.37%
—
—
—
0
17
98
963
—
—
—
0
23
96
947
—
Type 1 diabetes mellitus, With ophthalmic complications
E10.3 [45552380]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.82%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:1.37%
0
8
98
972
0
5
98
975
—
—
—
0
5
96
965
0
12
83
867
Neoplasm of uncertain or unknown behaviour: Connective and other soft tissue
D48.1 [45566694]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.00%
—
—
—
—
—
—
—
6
0
90
970
—
fusidic acid; ointment
D06AX01 [21602062]
—
—
—
—
—
—
9.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:2.50%
—
—
—
—
—
—
5
22
78
857
Intensive care
WX872 [2001310844]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
98
975
—
—
—
—
—
—
Sneezing/nasal congestion
R07 [2002000888]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
0
9
98
971
—
—
—
—
—
0
9
83
870
Other minor procedure in surgery of teeth, jaws, mouth and pharynx
TEW99 [2001302349]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
8
83
871
Photography of fundus of eye
XCK10 [2001301381]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
0
6
98
974
—
—
—
0
10
96
960
—
Laceration/cut
S18 [2002000983]
1.5e-01
—
—
—
—
1.3e+00
-1.7e-01
cases:7.14%
controls:6.22%
—
—
—
—
—
—
—
—
cases:9.38%
controls:2.68%
cases:7.23%
controls:8.42%
7
61
91
919
—
—
—
—
9
26
87
944
6
74
77
805
warfarin; oral, parenteral
B01AA03 [21600965]
2.8e-01
7.2e-01
—
—
—
8.3e-01
5.7e-01
cases:6.12%
controls:4.69%
cases:6.12%
controls:3.06%
—
—
—
—
—
—
cases:7.29%
controls:3.30%
cases:7.23%
controls:4.21%
6
46
92
934
6
30
92
950
—
—
—
7
32
89
938
6
37
77
842
Phakoemulsification with implantation of artificial lens in posterior chamber
CJE20 [2001301342]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
0
5
98
975
—
—
—
0
9
96
961
—
Neurosurgery
14 [38004459]
1.5e+00
—
—
—
—
2.2e+00
9.1e-01
cases:5.10%
controls:1.22%
—
—
—
—
—
—
—
—
cases:5.21%
controls:0.62%
cases:6.02%
controls:2.50%
5
12
93
968
—
—
—
—
5
6
91
964
5
22
78
857
Viral disease other/NOS
A77 [2002000211]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
0
5
96
965
—
Issue of medical certificate
Z02.7 [45537613]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
0
5
98
975
—
—
—
—
—
semaglutide; oral, parenteral
A10BJ06 [1501778]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:1.02%
—
—
—
—
—
0
6
96
964
0
9
83
870
Ultrasound examination of early pregnancy (before 12. postmenstrual week)
MA1AE [2001306827]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
Balloon angioplasty and drug eluding stent
AN4 [2000200166]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
0
6
98
974
—
—
—
—
—
0
5
83
874
Periodontal treatment by dental hygienist, extensive
SDE03 [2001310351]
8.8e-02
—
—
—
—
—
-1.0e+50
cases:5.10%
controls:4.69%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
5
46
93
934
—
—
—
—
—
0
8
83
871
Retained dental root
K08.3 [45543292]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.71%
0
8
98
972
—
—
—
—
—
0
15
83
864
Tinea unguium
B35.1 [45590850]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
98
975
—
—
—
—
—
—
Seborrhoeic keratosis
L82 [45548208]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
—
—
—
—
—
0
9
96
961
—
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
0.0e+00
-6.1e-02
—
—
—
-1.7e-01
-3.4e-03
cases:20.41%
controls:20.41%
cases:13.27%
controls:13.98%
—
—
—
—
—
—
cases:12.50%
controls:14.43%
cases:31.33%
controls:31.40%
20
200
78
780
13
137
85
843
—
—
—
12
140
84
830
26
276
57
603
Albumin [Mass/time] in Urine collected for unspecified duration
49002-9 [3050449]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
0
5
98
975
—
—
—
—
0
6
83
873
Myocardial infarction (acute) UNS unspecified coronary artery status
I21.99 [2000502444]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
Guidance concerning treatment of rash and skin
SPAT1156 [2001700257]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
0
8
96
962
—
formoterol, glycopyrronium bromide and budesonide
R03AL11 [715850]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.92%
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
0
9
98
971
0
7
98
973
—
—
—
—
—
ezetimibe; oral
C10AX09 [21601896]
—
—
-1.0e+50
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
0
5
98
975
—
—
—
—
Troponin T.cardiac [Mass/volume] in Serum or Plasma
6598-7 [3019800]
—
—
—
—
—
—
5.0e-02
—
—
—
—
—
—
—
—
—
—
—
—
cases:9.64%
controls:9.22%
—
—
—
—
—
—
8
81
75
798
theophylline; oral, parenteral, rectal
R03DA04 [21603332]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.12%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.91%
0
11
98
969
0
8
98
972
—
—
—
0
5
96
965
0
8
83
871
Assessment of need for rehabilitation and/or rehabilitation plan
SPAT1220 [2001700321]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
98
974
—
—
—
—
—
—
dextromethorphan; oral
R05DA09 [21603404]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
—
—
—
0
7
98
973
—
—
—
0
5
96
965
—
Knee X-ray examination without contrast
NG1AA [2001308049]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:0.91%
—
—
—
—
—
—
5
8
78
871
Chondrosarcoma of the spine
C41.22 [2000500694]
—
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:0.00%
—
—
—
—
—
—
5
0
78
879
dexamethasone and antiinfectives
S02CA06 [21605178]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
98
971
—
—
—
—
—
—
Carboxyhemoglobin/Hemoglobin.total in Venous blood
2032-1 [3010517]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:1.02%
—
0
5
98
975
—
—
—
0
5
96
965
0
9
83
870
dexamethasone
S01BA01 [21603618]
—
—
—
—
—
-1.0e+50
8.2e-01
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
cases:6.02%
controls:2.73%
—
—
—
—
—
0
7
96
963
5
24
78
855
Mitral (valve) prolapse
I34.1 [45552788]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
0
5
98
975
—
—
—
—
—
0
5
83
874
fluticasone furoate; nasal
R01AD12 [21605053]
3.0e-01
5.4e-01
—
—
-1.0e+50
—
3.8e-01
cases:10.20%
controls:7.76%
cases:6.12%
controls:3.67%
—
—
—
—
cases:0.00%
controls:0.71%
—
—
cases:8.43%
controls:5.92%
10
76
88
904
6
36
92
944
—
—
0
7
97
973
—
7
52
76
827
glucagon; nasal, parenteral
H04AA01 [21602778]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
0
9
98
971
—
—
—
—
—
0
5
83
874
Sprain and strain of ankle
S93.4 [45550848]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
98
974
—
—
—
—
—
—
Severe psychotic and other severe mental disorders
112 [2001600112]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
98
974
—
—
—
—
—
—
Three-surface restoration
SFA30 [2001310360]
—
—
—
—
—
8.4e-01
3.6e-01
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:2.78%
cases:10.84%
controls:7.85%
—
—
—
—
—
6
27
90
943
9
69
74
810
Chronic alcohol abuse
P15 [2002000811]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
6
98
974
—
—
—
—
—
0
6
83
873
Apixaban, dabigatran, edoxaban and rivaroxaban for the treatment of atrial fibrillation
290 [2001600222]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
—
—
0
10
98
970
—
—
—
—
0
6
96
964
—
Counselling and guidance related to ageing
SPAT1304 [2001700405]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
6
83
873
tretinoin; ointment
D10AD01 [21602293]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
Erythrocytes [Presence] in Urine by Automated
53292-9 [3041096]
—
—
—
—
—
9.6e-01
8.7e-01
—
—
—
—
—
—
—
—
—
—
cases:5.21%
controls:2.06%
cases:13.25%
controls:6.03%
—
—
—
—
—
5
20
91
950
11
53
72
826
SMOKING - SMOKE2: yes - SMOKE3: current - SMOKE5: occasional
SMOKING-1-1-2 [2002330117]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
98
975
—
—
—
—
—
—
Palpitations/awareness of heart
K04 [2002000547]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
—
—
—
—
—
—
0
11
83
868
Hypertension uncomplicated
K86 [2002000613]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.71%
—
—
—
—
—
—
0
15
83
864
Treatment of chronic ulcer or burn
SPAT1148 [2001700249]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:1.02%
—
—
—
—
—
0
5
96
965
0
9
83
870
Actinic keratosis
L57.0 [45591640]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
98
974
—
—
—
—
—
—
Cardiac arrhythmia NOS
K80 [2002000607]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:0.57%
—
—
—
—
—
0
6
96
964
0
5
83
874
Overall medication plan or its review
SPAT1252 [2001700353]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.82%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
0
8
98
972
0
5
98
975
—
—
—
—
0
6
83
873
Calculus of ureter
N20.1 [45582395]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
General Practice Dentistry
1223G0001X [38003675]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
8
83
871
Throat symptom/complaint
R21 [2002000891]
6.0e-01
—
—
—
—
—
—
cases:5.10%
controls:2.86%
—
—
—
—
—
—
—
—
—
—
—
—
5
28
93
952
—
—
—
—
—
—
Obstetrics / Gynecology
16 [38004461]
1.2e-01
—
—
—
—
—
6.3e-01
cases:11.22%
controls:10.10%
—
—
—
—
—
—
—
—
—
—
cases:16.87%
controls:9.78%
11
99
87
881
—
—
—
—
—
14
86
69
793
hydrocortisone and antiinfectives
S01CA03 [21603654]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.37%
—
0
5
98
975
—
—
—
—
0
12
83
867
Internal derangement of knee, unspecified
M23.9 [45567507]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
98
972
—
—
—
—
—
—
metformin and sitagliptin
A10BD07 [21600772]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:0.82%
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
0
8
98
972
0
7
98
973
—
—
—
—
—
Feeling anxious/nervous/tense
P01 [2002000798]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.53%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
0
15
98
965
—
—
—
—
0
9
96
961
—
insulin glargine; parenteral
A10AE04 [21600739]
-1.0e+50
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
cases:0.00%
controls:2.45%
cases:0.00%
controls:2.24%
—
—
—
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:2.37%
—
—
0
24
98
956
0
22
98
958
—
—
0
6
97
974
0
23
96
947
—
Reagin Ab [Titer] in Serum by VDRL
50690-7 [3029634]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
98
975
—
—
—
—
—
—
Dermatitis, unspecified
L30.9 [45572271]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
0
7
98
973
—
—
—
—
—
Senile macular degeneration (atrophic)(exudative)
H35.31 [2000502315]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
dexamethasone
S02BA06 [21605168]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:1.33%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
0
13
98
967
—
—
—
—
0
7
96
963
—
Restoration involving the entire crown of the tooth
SFA40 [2001310361]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
cases:0.00%
controls:2.50%
—
0
7
98
973
—
—
—
—
0
22
83
857
Monocytes [#/volume] in Blood
26484-6 [3001604]
1.3e-01
7.4e-01
—
—
—
1.8e-01
6.1e-01
cases:9.18%
controls:8.16%
cases:9.18%
controls:4.59%
—
—
—
—
—
—
cases:7.29%
controls:6.19%
cases:20.48%
controls:12.29%
9
80
89
900
9
45
89
935
—
—
—
7
60
89
910
17
108
66
771
Adjuvant radiotherapy
WF003 [2001310702]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:5.21%
controls:0.00%
—
—
—
—
—
—
—
5
0
91
970
—
levofloxacin
S01AE05 [43534860]
—
-1.0e+50
—
—
—
—
1.4e+00
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
cases:7.23%
controls:1.93%
—
0
5
98
975
—
—
—
—
6
17
77
862
Beta 1 globulin [Mass/volume] in Serum or Plasma by Electrophoresis
32730-4 [3043723]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
98
974
—
—
—
—
—
—
Gingivitis (chronic) NOS
K05.10 [2000502717]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
98
964
—
—
—
—
—
—
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
3.6e-01
3.7e-01
—
—
-1.0e+50
—
2.3e-01
cases:8.16%
controls:5.82%
cases:5.10%
controls:3.57%
—
—
—
—
cases:0.00%
controls:0.82%
—
—
cases:13.25%
controls:10.81%
8
57
90
923
5
35
93
945
—
—
0
8
97
972
—
11
95
72
784
Foreign body in skin
S15 [2002000980]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
98
974
—
—
—
—
—
—
Carbon dioxide [Partial pressure] in Venous blood
2021-4 [3021447]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:0.00%
controls:1.03%
—
—
—
0
8
98
972
—
—
—
0
10
96
960
—
Medication, disinfection of root canals
SGC00 [2001310392]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
0
5
98
975
—
—
—
—
0
10
83
869
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
0
5
98
975
—
—
—
—
—
0
11
83
868
orphenadrine, combinations
M03BC51 [21604113]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
0
8
96
962
—
Methadone [Presence] in Urine by Screen method
19550-3 [3028707]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
6
83
873
Depressive episode
F32 [45595904]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
98
974
—
—
—
—
—
—
Boil/carbuncle
S10 [2002000975]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
—
—
—
—
0
6
98
974
—
—
—
—
—
—
Mouth/tongue/lip symptom/complaint
D20 [2002000319]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
1.8e-01
9.0e-01
—
—
—
4.1e-01
-9.6e-02
cases:15.31%
controls:13.16%
cases:16.33%
controls:7.35%
—
—
—
—
—
—
cases:11.46%
controls:7.94%
cases:19.28%
controls:20.82%
15
129
83
851
16
72
82
908
—
—
—
11
77
85
893
16
183
67
696
miconazole
D01AC02 [21601921]
—
-1.0e+50
—
—
—
—
-1.0e+50
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
0
5
98
975
—
—
—
—
0
10
83
869
denosumab; parenteral
M05BX04 [21604169]
—
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:1.02%
—
0
5
98
975
—
—
—
0
6
96
964
0
9
83
870
General Practice
1 [38004446]
-2.6e-01
—
—
—
—
4.1e-01
-3.5e-01
cases:9.18%
controls:11.63%
—
—
—
—
—
—
—
—
cases:7.29%
controls:4.95%
cases:9.64%
controls:13.20%
9
114
89
866
—
—
—
—
7
48
89
922
8
116
75
763
Chronic hypertension
205 [2001600203]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
8
83
871
Cerebral aneurysm, nonruptured
I67.1 [45538401]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
pimecrolimus
D11AH02 [21602339]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
8
83
871
Fracture of lower end of radius
S52.5 [45573842]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.63%
—
—
—
—
—
—
—
—
—
—
—
—
0
16
98
964
—
—
—
—
—
—
Acute stress reaction
F43.0 [45591139]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
7
83
872
Blepharitis
H01.0 [45533180]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
0
9
83
870
Unspecified dementia
F03 [45566772]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
7
83
872
Overweight
T83 [2002001126]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
98
975
—
—
—
—
—
—
Respiratory and circulatory monitoring
WX700 [2001310817]
8.7e-01
-1.0e+50
—
—
—
2.2e+00
—
cases:6.12%
controls:2.65%
cases:0.00%
controls:0.82%
—
—
—
—
—
—
cases:5.21%
controls:0.62%
—
—
6
26
92
954
0
8
98
972
—
—
—
5
6
91
964
—
Gastro-oesophageal reflux disease with oesophagitis
K21.0 [45543296]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
—
—
—
—
—
—
0
10
83
869
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
-1.0e-01
2.3e-02
-1.0e+50
—
-1.0e+50
-6.0e-01
-4.8e-01
cases:21.43%
controls:23.16%
cases:16.33%
controls:16.02%
cases:0.00%
controls:2.04%
—
—
cases:0.00%
controls:1.53%
cases:10.42%
controls:17.42%
cases:25.30%
controls:35.27%
21
227
77
753
16
157
82
823
0
20
98
960
—
0
15
97
965
10
169
86
801
21
310
62
569
acetylsalicylic acid, combinations excl. psycholeptics
N02BA51 [21604320]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.63%
cases:0.00%
controls:1.53%
—
—
—
—
—
—
cases:0.00%
controls:1.34%
cases:0.00%
controls:1.59%
0
16
98
964
0
15
98
965
—
—
—
0
13
96
957
0
14
83
865
Extraction of root of tooth
EBA30 [2001301929]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
98
975
—
—
—
—
—
—
Constipation
K59.0 [45557663]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
8
83
871
escitalopram; oral
N06AB10 [21604718]
—
—
—
—
—
—
7.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:2.84%
—
—
—
—
—
—
5
25
78
854
naproxen; oral, rectal
M01AE02 [21603968]
-1.2e-01
—
—
—
—
—
-1.9e-01
cases:8.16%
controls:9.08%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:7.17%
8
89
90
891
—
—
—
—
—
5
63
78
816
allopurinol; oral, parenteral
M04AA01 [21604131]
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
0
6
97
974
—
—
Albumin/Creatinine [Ratio] in Urine
32294-1 [3020682]
—
—
-1.0e+50
—
—
—
-8.0e-01
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:6.02%
controls:12.51%
—
—
0
5
98
975
—
—
—
5
110
78
769
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
-1.0e+50
—
—
—
—
—
5.9e-01
cases:0.00%
controls:2.04%
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:3.41%
0
20
98
960
—
—
—
—
—
5
30
78
849
Counselling and guidance which enhance independent living
R2130 [2001310196]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.92%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.25%
0
9
98
971
—
—
—
—
—
0
11
83
868
rivaroxaban; oral
B01AF01 [43534761]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.63%
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
0
16
98
964
0
10
98
970
—
—
—
—
—
Open wound of scalp
S01.0 [45592468]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
98
969
—
—
—
—
—
—
dutasteride; oral
G04CB02 [21602676]
-1.0e+50
-1.0e+50
—
—
—
—
—
cases:0.00%
controls:1.22%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
0
12
98
968
0
5
98
975
—
—
—
—
—
Sequelae of cerebral infarction
I69.3 [45533476]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
0
7
98
973
—
—
—
—
—
Confocal scanning laser ophthalmoscopy
391999003 [4189584]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
98
975
—
—
—
—
—
—
Basic examination of mouth
SAA02 [2001310275]
1.3e-01
2.8e-01
—
—
—
2.5e-01
1.5e-01
cases:16.33%
controls:14.59%
cases:7.14%
controls:5.51%
—
—
—
—
—
—
cases:8.33%
controls:6.60%
cases:20.48%
controls:18.20%
16
143
82
837
7
54
91
926
—
—
—
8
64
88
906
17
160
66
719
piroxicam; oral, parenteral, rectal
M01AC01 [21603961]
—
1.7e+00
—
—
—
—
—
—
—
cases:6.12%
controls:1.22%
—
—
—
—
—
—
—
—
—
—
—
6
12
92
968
—
—
—
—
—
codeine and paracetamol
N02AJ06 [1123647]
-1.1e-02
—
—
—
—
9.7e-01
5.5e-01
cases:10.20%
controls:10.31%
—
—
—
—
—
—
—
—
cases:7.29%
controls:2.89%
cases:16.87%
controls:10.47%
10
101
88
879
—
—
—
—
7
28
89
942
14
92
69
787
ticagrelor; oral
B01AC24 [40252640]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
Telehealth
OMOP5556618 [722455]
-1.1e-01
1.5e-01
—
—
—
2.8e-01
7.8e-04
cases:21.43%
controls:23.37%
cases:10.20%
controls:8.88%
—
—
—
—
—
—
cases:10.42%
controls:8.04%
cases:14.46%
controls:14.45%
21
229
77
751
10
87
88
893
—
—
—
10
78
86
892
12
127
71
752
sitagliptin; oral
A10BH01 [21600784]
-1.0e+50
-1.0e+50
-1.0e+50
—
-1.0e+50
-1.0e+50
-1.0e+50
cases:0.00%
controls:1.43%
cases:0.00%
controls:1.12%
cases:0.00%
controls:0.51%
—
—
cases:0.00%
controls:0.51%
cases:0.00%
controls:1.34%
cases:0.00%
controls:1.93%
0
14
98
966
0
11
98
969
0
5
98
975
—
0
5
97
975
0
13
96
957
0
17
83
862
Salmonella sp identified in Stool by Organism specific culture
20955-1 [3004716]
—
—
—
—
—
-1.0e+50
-1.0e+50
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.62%
cases:0.00%
controls:0.68%
—
—
—
—
—
0
6
96
964
0
6
83
873
Cardiorespiratory global assessment
SPAT1081 [2001700182]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
—
—
0
10
98
970
—
—
—
—
—
—
drospirenone and ethinylestradiol
G03AA12 [21602485]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:1.02%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
0
10
98
970
—
—
—
—
—
0
8
83
871
X-ray examination of the lungs in one projection
GD1PA [2001303645]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.82%
—
—
—
—
—
—
—
—
—
—
—
—
0
8
98
972
—
—
—
—
—
—
medroxyprogesterone; oral, parenteral
G03DA02 [21602540]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.68%
—
—
—
—
—
—
0
6
83
873
Primary total prosthetic replacement of knee joint without patellar part
NGB20 [2001308094]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.61%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.52%
cases:0.00%
controls:0.80%
0
6
98
974
—
—
—
—
0
5
96
965
0
7
83
872
Paroxysmal atrial fibrillation
I48.0 [45581776]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.48%
—
—
—
—
—
—
0
13
83
866
Disorder of ligament
M24.2 [45557839]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.57%
—
—
—
—
—
—
0
5
83
874
Therapeutic discussion
SPAT1240 [2001700341]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.12%
—
—
—
—
—
—
—
—
—
—
—
—
0
11
98
969
—
—
—
—
—
—
Conjunctivitis, unspecified
H10.9 [45591253]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.80%
—
—
—
—
—
—
0
7
83
872
orphenadrine (citrate); oral, parenteral
M03BC01 [21604112]
—
—
—
—
—
—
1.5e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.02%
controls:5.23%
—
—
—
—
—
—
5
46
78
833
insulin degludec; parenteral
A10AE06 [43534747]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
—
—
—
—
—
—
0
8
83
871
desogestrel
G03AC09 [21602505]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.61%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:0.00%
controls:0.93%
—
—
0
6
98
974
0
5
98
975
—
—
—
0
9
96
961
—
celecoxib
L01XX33 [21603805]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.23%
controls:1.48%
—
—
—
—
—
—
6
13
77
866
Pelvic, hip and femur extensive MRI examination with high intensity magnet
NE1CG [2001307805]
—
—
—
—
—
1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:5.21%
controls:0.00%
—
—
—
—
—
—
—
5
0
91
970
—
Caries of cementum
K02.2 [45591568]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.51%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.14%
0
5
98
975
—
—
—
—
—
0
10
83
869

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
64
283
3.91
11.68
2.9
1.6
—
—
—
0
0
64
285
3.87
11.52
3.8
2.1
—
—
—
0
0
20
19
12.52
11.32
1.2
1.4
—
—
—
0
0
77
395
3.98
11.07
3.9
2.5
—
—
estimate
—
0
0
24
65
4.42
8.43
1.3
1.1
—
—
—
0
0
20
47
4.96
8.33
2.3
2.0
1.83
2.95
ug/l
1.90
15
35
30
112
3.29
6.57
8.8
9.0
0.34
1.32
mmol/l
0.97
25
93
30
116
3.16
6.18
8.8
8.8
7.40
7.42
ph
0.72
13
68
75
512
2.38
4.53
9.0
6.6
4.87
4.28
e9/l
0.27
67
436
46
266
2.23
4.02
5.2
4.6
—
—
—
0
0
72
504
2.18
3.82
5.2
5.7
0.21
0.20
e9/l
0.06
61
436
23
102
2.58
3.59
2.1
1.9
—
—
—
0
0
69
485
2.09
3.50
5.3
5.7
0.57
0.57
e9/l
0.02
60
413
62
421
2.05
3.43
7.3
6.4
1.20
1.21
mmol/l
0.64
55
386
70
498
2.07
3.39
5.6
5.7
1.74
1.84
e9/l
0.53
61
437
69
489
2.06
3.37
5.3
5.7
0.04
0.04
e9/l
0.05
60
416
48
302
2.02
3.24
4.9
5.7
—
—
—
0
0
42
252
2.06
3.22
5.2
4.0
—
—
—
0
0
59
411
1.91
2.88
4.3
3.9
34.94
35.94
g/l
0.67
54
392
8
19
4.45
2.73
1.0
1.1
—
—
—
0
0
65
474
1.87
2.69
7.1
7.1
1.21
1.21
mmol/l
0.05
55
424
63
461
1.83
2.53
15.2
13.3
1.27
1.27
inr
0.01
49
376
55
389
1.81
2.44
9.4
10.4
0.00
0.00
e9/l
0.49
42
310
17
82
2.26
2.20
14.4
10.6
—
—
—
0
0
7
19
3.85
2.19
1.6
1.3
—
—
—
0
0
6
14
4.46
2.18
2.5
2.6
69.83
62.24
%
—
6
14
74
588
1.75
2.07
6.6
4.8
6.42
6.72
mmol/l
0.77
68
557
35
234
1.72
1.79
1.4
1.3
—
—
—
0
0
5
13
3.97
1.73
2.8
3.2
12.14
12.78
mg/l
—
5
13
0
42
0.00
1.56
0.0
2.8
—
288.40
—
0
15
0
44
0.00
1.55
0.0
1.1
—
—
—
0
0
12
59
2.16
1.50
2.6
5.7
—
—
—
0
0
5
16
3.22
1.45
1.8
1.4
—
—
—
0
0
104
955
2.12
1.44
18.8
12.9
—
—
—
0
0
17
98
1.86
1.40
1.8
1.4
—
—
—
0
0
13
68
2.03
1.40
1.7
2.4
0.19
0.21
g/l
0.75
13
61
38
276
1.57
1.38
2.2
3.6
7.42
7.39
ph
2.67
26
183
23
147
1.71
1.37
2.0
2.5
0.82
0.83
mmol/l
0.26
23
141
101
918
1.94
1.36
20.6
14.2
31.97
23.73
mg/l
1.63
89
736
96
860
1.77
1.35
4.9
5.1
2.03
1.92
mu/l
0.36
84
786
11
196
0.51
1.28
1.5
1.4
1.78
2.68
g/l
—
6
110
20
126
1.71
1.25
2.4
6.6
0.98
1.07
mmol/l
0.85
20
117
18
110
1.76
1.24
1.6
2.3
4.33
5.70
umol/l
1.28
18
99
22
143
1.67
1.23
2.3
1.7
—
—
—
0
0
72
613
1.48
1.17
4.7
4.5
—
399.56
—
0
9
11
59
1.96
1.12
6.5
2.7
—
—
—
0
0
21
139
1.63
1.10
9.6
7.3
103.76
104.24
mmol/l
0.16
21
139
0
29
0.00
0.99
0.0
1.2
—
0.79
—
0
29
8
44
1.88
0.88
3.0
4.6
—
—
—
0
0
106
1008
1.83
0.84
32.4
21.6
90.77
91.32
fl
0.49
106
997
106
1009
1.82
0.84
32.4
21.6
30.10
30.44
pg
1.17
106
998
106
1009
1.82
0.84
33.8
22.2
39.25
40.79
%
2.87
106
998
18
124
1.54
0.81
1.6
1.5
—
—
—
0
0
0
25
0.00
0.80
0.0
1.3
—
—
—
0
0
16
227
0.66
0.78
1.1
1.3
1.48
1.20
u/ml
—
5
64
0
27
0.00
0.78
0.0
1.1
—
0.51
—
0
5
104
988
1.66
0.76
13.8
10.3
25.49
25.59
u/l
0.02
99
957
9
56
1.66
0.74
1.2
1.6
—
—
—
0
0
32
252
1.38
0.74
2.6
2.9
0.34
0.35
e6/l
0.02
24
173
5
25
2.04
0.73
1.8
1.4
351.80
425.05
e6/l
—
5
20
5
25
2.04
0.73
1.8
1.2
353.80
3.35
e6/l
—
5
20
106
1010
1.80
0.72
32.8
21.7
130.07
136.65
g/l
4.03
106
998
10
61
1.70
0.71
3.2
4.0
7.44
7.43
ph
—
10
50
34
279
1.31
0.60
5.7
3.8
0.00
0.00
estimate
-0.00
12
87
0
23
0.00
0.59
0.0
1.3
—
—
—
0
0
57
504
1.26
0.56
4.8
4.0
0.00
0.00
estimate
-0.00
12
97
85
904
0.76
0.55
6.4
6.9
38.20
40.03
mmol/mol
1.02
73
847
6
96
0.60
0.55
2.2
2.6
0.10
0.31
e6/l
—
6
90
12
84
1.48
0.52
1.8
2.1
—
0.00
estimate
—
0
22
57
510
1.24
0.49
4.7
4.0
0.00
0.00
estimate
-0.00
11
87
10
68
1.52
0.49
6.8
4.0
1.40
0.47
%
—
5
15
88
927
0.77
0.47
4.7
5.6
4.33
4.50
mmol/l
0.82
76
870
9
128
0.68
0.46
1.4
1.4
—
365.56
—
0
36
7
50
1.43
0.46
2.0
2.1
—
0.00
estimate
—
0
18
14
104
1.40
0.46
1.3
1.5
—
—
—
0
0
33
280
1.25
0.45
3.6
3.3
—
—
—
0
0
88
925
0.78
0.44
4.7
5.4
1.48
1.46
mmol/l
0.13
76
862
0
16
0.00
0.41
0.0
1.7
—
4.06
—
0
16
0
16
0.00
0.41
0.0
1.7
—
1.20
—
0
16
0
16
0.00
0.41
0.0
1.7
—
105.94
—
0
16
0
16
0.00
0.41
0.0
3.6
—
1.12
—
0
16
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
90
941
0.79
0.40
5.3
6.3
2.40
2.60
mmol/l
1.42
79
879
0
18
0.00
0.40
0.0
1.1
—
—
—
0
0
55
498
1.20
0.40
4.7
3.9
0.00
0.00
estimate
-0.00
11
90
13
98
1.37
0.39
1.5
1.6
—
—
—
0
0
0
19
0.00
0.39
0.0
1.1
—
—
—
0
0
35
306
1.21
0.36
2.7
3.1
29.73
250.76
e6/l
0.51
26
228
12
92
1.34
0.33
2.3
3.9
7.38
7.34
ph
—
6
62
43
387
1.18
0.32
5.2
3.8
0.00
0.01
estimate
0.49
11
74
38
421
0.85
0.29
1.7
2.0
1.14
1.32
mmol/l
1.18
31
369
74
700
1.17
0.28
4.5
4.0
14.49
14.96
pmol/l
0.75
65
642
17
141
1.24
0.28
1.9
1.6
—
—
—
0
0
52
480
1.15
0.27
2.0
2.1
86.77
95.31
pmol/l
0.61
27
240
44
404
1.15
0.25
4.3
3.6
6.20
6.19
ph
0.02
25
228
27
240
1.16
0.23
4.7
4.4
1.02
1.02
kg/l
0.97
20
159
12
145
0.81
0.22
1.1
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
2.0
—
11.90
—
0
11
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
0.37
—
0
10
0
10
0.00
0.21
0.0
1.6
—
3.18
—
0
5
0
10
0.00
0.21
0.0
1.2
—
5.87
—
0
10
0
10
0.00
0.21
0.0
2.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
2.85
—
0
10
0
10
0.00
0.21
0.0
1.3
—
7.97
—
0
10
0
10
0.00
0.21
0.0
1.7
—
48.50
—
0
10
0
12
0.00
0.21
0.0
1.1
—
27.92
—
0
12
0
13
0.00
0.21
0.0
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
0.49
—
0
8
0
14
0.00
0.20
0.0
1.1
—
—
—
0
0
37
341
1.13
0.19
3.2
3.9
11.50
122.94
e6/l
1.96
27
233
22
196
1.15
0.18
7.9
4.5
—
—
—
0
0
34
368
0.89
0.18
2.5
3.4
7.62
7.63
mmol/l
0.00
23
315
6
75
0.79
0.16
1.5
1.5
—
—
—
0
0
86
883
0.89
0.15
3.9
4.6
1.15
1.26
mmol/l
1.34
75
820
10
84
1.21
0.14
1.7
4.6
342.60
231.83
ng/l
—
10
75
34
361
0.92
0.12
3.1
4.2
3.19
9.67
mg/mmol
1.93
16
231
90
918
0.90
0.11
4.6
5.3
5.75
6.01
mmol/l
2.00
74
835
5
45
1.12
0.10
2.0
1.9
—
—
—
0
0
5
60
0.83
0.08
1.0
1.3
—
—
—
0
0
9
84
1.08
0.07
1.3
1.4
—
—
—
0
0
29
277
1.06
0.06
4.6
3.5
0.00
0.00
estimate
-0.00
11
70
34
352
0.95
0.05
2.6
3.5
24.68
62.16
mg/l
1.68
17
232
28
272
1.04
0.02
2.6
3.3
—
0.33
—
0
6
36
368
0.97
0.02
2.5
3.3
—
—
—
0
0
40
405
0.98
0.00
4.3
4.0
31.23
41.74
ng/l
0.42
30
291
18
181
0.99
0.00
1.5
1.7
1438.27
1173.60
nmol/l
0.40
11
136
0
5
0.00
0.00
0.0
1.8
—
11.18
—
0
5
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
0.67
—
0
6
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
153.67
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
14.68
—
0
9
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
86.05
—
0
8
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
80.67
—
0
6
0
8
0.00
-0.00
0.0
1.1
—
97.75
—
0
8
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
9
97
0.92
-0.00
2.7
1.7
319.67
389.10
nmol/l
—
9
88
8
82
0.97
-0.00
1.1
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.1
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded from FinRegistry analyses (omitted endpoint).

Relationships between endpoints

↥

Index endpoint: C3_CHONDROSARCOMA – Chondrosarcoma

GWS hits: -

This endpoint is excluded from FinRegistry analyses (omitted endpoint).